LUPIN— Lupin

The Indian pharmaceutical and healthcare sectors are set for a varied performance in the March quarter, with hospitals anticipating robust growth while generic drug manufacturers face headwinds from lost Revlimid sales and pricing pressures.

Jefferies identifies Sun Pharma, Lupin, and Torrent Pharma as frontrunners in India's emerging generic Semaglutide market, driven by surging demand for affordable diabetes and obesity treatments.